Printer Friendly

OSTEOTECH SIGNS AGREEMENT FOR REVOLUTIONARY PLASMA TISSUE STERILIZATION TECHNOLOGY

 OSTEOTECH SIGNS AGREEMENT FOR REVOLUTIONARY PLASMA TISSUE
 STERILIZATION TECHNOLOGY
 SHREWSBURY, N.J., Aug. 11 /PRNewswire/ -- Osteotech, Inc., (NASDAQ: OSTE) the world's largest processor of human musculoskeletal tissue, announced today that it has entered into an agreement with Abtox Inc., a Chicago area private company which develops unique medical sterilization systems. Under the terms of the agreement Osteotech will acquire equipment and the exclusive worldwide license to use Abtox's proprietary vapor phase plasma technology, known as Plazlyte(TM) Sterilization System, for the sterilization of musculoskeletal tissue.
 "Although our current processing method is considered state-of-the- art and provides efficacious bone tissue for transplantation," said Patrick A. McBrayer, Osteotech's president and chief executive officer, "we have a responsibility to continually enhance our existing technology. We believe that Plazlyte could revolutionize tissue sterilization."
 Bone tissue processed by Osteotech is used by orthopaedic, neurological and oral surgeons to replace and repair bone damaged by trauma or disease. The company has processed over 425,000 tissues since it started processing in 1987.
 According to Abtox President and Chief Executive Officer, Ross A. Caputo, Ph.D., "Plazlyte, a virucidal and sporicidal process, is anticipated to have the unique capability of sterilizing bone tissue without causing the problems typically associated with many traditional sterilization methods."
 Robert K. O'Leary, Ph.D., executive vice president, research and development at Osteotech said, "Once installed, the Plazlyte process would have the potential to sterilize bone tissue using ambient temperatures, and a non-toxic process. Implementation of this technology would be one more step in our continuing effort to provide the transplant community with the safest and highest quality bone tissue."
 The agreement calls for Osteotech to pay an aggregate of $600,000 over a twenty-four month period and is subject to the completion of certain milestones including testing and validation of the Abtox equipment. The agreement also requires Osteotech to pay a royalty on all tissue it processes using the technology.
 Osteotech, Inc. headquartered in Shrewsbury, N.J., is a leading processor of human bone and bone connective tissue for transplantation for the American Red Cross, the Musculoskeletal Transplant Foundation and Biolmplant Services, a subsidiary of the Eurotransplant Foundation, and is an innovator in the development of products for musculoskeletal surgery.
 -0- 8/11/92
 /CONTACT: Michael J. Jeffries of Osteotech, 908-542-2800/
 (OSTE) CO: Osteotech, Inc. ST: New Jersey IN: MTC SU:


LR-OS -- NY019 -- 8849 08/11/92 09:32 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 11, 1992
Words:398
Previous Article:BOSTON TECHNOLOGY SELECTED BY JAPAN'S NTT MOBILE IN TELECOMMUNICATIONS EQUIPMENT TENDER
Next Article:INTERPHARM LABORATORIES LTD. REPORTS EARNINGS AND INCOME FOR THE SECOND QUARTER OF 1992
Topics:


Related Articles
OSTEOTECH'S POLYACTIVE POLYMER PRESENTED AT INTERNATIONAL BIOMATERIALS MEETING
OSTEOTECH ANNOUNCES BROAD EUROPEAN AND U.S. VENTURE WITH APS-MATERIALS TO EXPAND ORTHOPAEDIC AND DENTAL COATING SERVICES
OSTEOTECH SIGNS EXCLUSIVE AGREEMENT FOR DEVICES AND INSTRUMENTS FOR TREATMENT OF BONE TRAUMA
OSTEOTECH ANNOUNCES 35 PERCENT REVENUE INCREASE FOR SIX-MONTH PERIOD; EARNINGS ALSO INCREASE SIGNIFICANTLY
OSTE0TECH EXPANDS ITS EUROPEAN COATING SERVICES FOR ORTHOPAEDIC AND DENTAL IMPLANTS
3M AND ABTOX SIGN DISTRIBUTION AGREEMENT FOR CANADA AND EUROPE FOR NEW STERILIZATION TECHNOLOGY
Premier and AbTox Inc. Announce Agreement
Osteotech Announces Agreement With DePuy Orthopaedics, DePuy Acromed and LifeNet to Provide Private Label DBM Carrier Product to Hospital Market.
Osteotech Announces Election of New President and Chief Operating Officer.
Osteotech Enters Into Single Source Agreement With Novation.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters